Question 32603 — pharmacy and medications

Summary

Mrs. Marie-Pierre Rixain draws the attention of the Minister of Solidarity and Health to the subject of stopping the use of tamoxifen by many women after breast cancer. On June 18, 2020, a study published in the Journal of Clinical Oncology evaluated taking a drug to prevent breast cancer relapses. One year after starting treatment, in one in six patients (16%), the blood dosage shows poor monitoring of the tamoxifen prescription. Other studies indicate that at 5 years, half of patients no longer take tamoxifen. This study highlights both the importance of raising awareness among at-risk populations about potential relapses and the cost induced by poor compliance with this treatment for any type of cancer. This financial cost is far from negligible since, according to a study published in 2017 in the British Medical Journal, it would amount to between $55,000 and $150,000 per patient each year. Targeted interventions to encourage patient adherence to treatment are therefore necessary and can significantly improve the short-term outcome of breast cancer. Also, she would like to know the provisions that her ministry intends to establish to promote information and awareness of the public concerned about the continuous use of tamoxifen treatment.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.